Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical trial of MGCD 265 in patients with Axl-positive non-small cell lung cancer

Next Previous
Trial Profile

Clinical trial of MGCD 265 in patients with Axl-positive non-small cell lung cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Mar 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glesatinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors MethylGene

    • Most Recent Events

    • 09 Mar 2016 In Sept 2015, results of this trial were presented at the World Conference on Lung Cancer 2015, as per Mirati Therapeutics media release.
    • 11 Sep 2015 According to a Mirati Therapeutics media release, the results from first non-small cell lung cancer patient with AXL gene amplification enrolled in the phase 1b expansion cohort will be presented at the Association of Lung Cancer (IASLC) 16th World Conference on Lung Cancer.
    • 11 Mar 2015 Status changed from not yet recruiting to recruiting, based on information in a Mirati Therapeutics media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top